Biomarker Testing Services Market Size & Growth Forecast 2026–2035, By Segments (Service, Application, End Use, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Biomarker Testing Services Market size was more than USD 687.55 Million in 2025 and is set to grow at a 8.7% CAGR between 2026 and 2035, surpassing USD 1.58 Billion by 2035. The industry revenue for 2026 is estimated at USD 739.54 million.
Get more details on this report
Request Free Sample ReportBiomarker Testing Services Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 49.00% market share in 2025, supported by advanced clinical testing infrastructure, integrated healthcare networks, and consistent demand from precision medicine and drug development programs.
- Asia Pacific is expected to grow at a 9.83% CAGR as expanding diagnostic capacity, personalized medicine adoption, and increasing pharmaceutical research drive demand for specialized testing services.
Segment Momentum
- Oncology accounted for a 53.95% share in 2025 due to extensive biomarker use in cancer detection, patient stratification, treatment selection, and disease monitoring across clinical practice and research.
- Drug Discovery & Development is growing rapidly as biomarker testing is increasingly integrated earlier in development workflows to improve candidate selection, identify responsive populations, and measure treatment effects.
Market Expansion Drivers
- Growing demand for personalized medicine accelerating biomarker testing adoption in clinical research.
- Rising oncology prevalence increasing need for predictive and diagnostic biomarker analysis services.
- Pharmaceutical outsourcing of biomarker validation improving drug development efficiency and regulatory approvals.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading companies in the biomarker testing services market include IQVIA Holdings Inc. (United States), Thermo Fisher Scientific Inc. (United States), Charles River Laboratories International, Inc. (United States), Laboratory Corporation of America Holdings (United States), ICON plc (Ireland), Eurofins Scientific SE (Luxembourg), SGS S.A. (Switzerland), Syneos Health, Inc. (United States), Intertek Group plc (United Kingdom), BioAgilytix Labs, LLC (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As drug developers and research institutions shift toward patient stratification strategies, the biomarker testing services market is seeing stronger demand from clinical programs designed to match therapies with specific molecular profiles. Biomarker analysis has become central to trial design because it helps identify responsive subpopulations, refine inclusion criteria, and improve the likelihood that investigational therapies show measurable benefit in targeted cohorts. This is influencing market adoption by increasing reliance on specialized external testing partners that can deliver assay development, sample analysis, and data interpretation with the consistency needed for precision-focused studies.
Rising oncology prevalence increasing need for predictive and diagnostic biomarker analysis services
The growing burden of cancer is intensifying the use of molecular testing to guide diagnosis, treatment selection, and disease monitoring, which is reinforcing demand for the biomarker testing services market. Oncology care increasingly depends on predictive and diagnostic biomarkers to distinguish tumor subtypes, detect actionable mutations, and support therapy decisions tied to specific biological signals. In practice, this drives steady service requirements from hospitals, cancer centers, and biopharma sponsors seeking high-sensitivity testing platforms and validated workflows that can support both research use and clinically relevant evidence generation.
Pharmaceutical outsourcing of biomarker validation improving drug development efficiency and regulatory approvals
Pharmaceutical companies are outsourcing biomarker validation to specialized service providers as development programs become more complex and regulators place greater emphasis on analytically robust companion and supportive diagnostics. This is encouraging market growth in the biomarker testing services market by shifting critical validation work to partners with established laboratory infrastructure, technical expertise, and quality systems that can accelerate study timelines and reduce internal resource burdens. The outsourcing model also improves development efficiency by helping sponsors generate standardized biomarker evidence that is more readily aligned with regulatory expectations for patient selection, endpoint support, and submission-ready data packages.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing demand for personalized medicine accelerating biomarker testing adoption in clinical research | 2.00% | High | North America, Europe | High | Near Term |
| Rising oncology prevalence increasing need for predictive and diagnostic biomarker analysis services | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Pharmaceutical outsourcing of biomarker validation improving drug development efficiency and regulatory approvals | 1.50% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 49.00% share of the biomarker testing services market in 2025, backed by the region’s established clinical testing infrastructure, broad access to advanced diagnostic platforms, and close integration between laboratories, hospitals, and biopharma research activity. Market leadership is reinforced by routine use of biomarker-based testing in oncology and precision medicine workflows, where service providers benefit from steady sample volumes, strong reimbursement familiarity in specialized settings, and ongoing demand from drug development programs that require validated testing support across clinical trials and treatment selection.
Asia Pacific is projected to expand at a 9.83% CAGR over the forecast period, with growth in the biomarker testing services market being fueled by the rapid expansion of diagnostic capacity, rising adoption of personalized medicine, and increasing use of biomarker analysis in both clinical practice and regional research programs. Demand is accelerating as healthcare systems broaden access to advanced testing, while pharmaceutical and biotechnology activity across the region creates more practical need for outsourced and specialized laboratory services that can support patient stratification, companion diagnostics, and translational research.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes biomarker testing services supported by robust clinical validation and standardized laboratory practices. Healthcare institutions in Germany are strengthening collaborations with diagnostic providers to improve testing quality and support personalized therapeutic approaches.
France 🇫🇷
Personalized Care SupportFrance continues to strengthen biomarker testing services through broader integration into personalized treatment pathways. Healthcare organizations in France are increasing access to molecular diagnostics while improving coordination between laboratories, clinicians, and pharmaceutical stakeholders.
Italy 🇮🇹
Hospital Laboratory ModernizationItaly is modernizing biomarker testing services by expanding advanced diagnostic capabilities within hospital laboratory networks. Clinical laboratories in Italy are adopting standardized molecular testing processes that improve diagnostic consistency and support personalized patient management.
Japan 🇯🇵
Companion Diagnostics IntegrationJapan is expanding biomarker testing services alongside the increasing use of companion diagnostics in clinical care. Laboratories in Japan are prioritizing highly accurate molecular testing platforms that support treatment selection and improve diagnostic efficiency across specialized healthcare settings.
South Korea 🇰🇷
Advanced Genomic ServicesSouth Korea is investing in biomarker testing services that integrate genomic technologies into routine clinical workflows. Diagnostic providers in South Korea are enhancing laboratory capabilities to deliver faster and more comprehensive biomarker analysis for precision healthcare applications.
United States 🇺🇸
Precision Medicine ExpansionThe U.S. biomarker testing services market is advancing through broader adoption of precision medicine across oncology, immunology, and rare diseases. Clinical laboratories and healthcare providers in the U.S. are expanding molecular testing capabilities to support targeted therapies and personalized treatment decisions.
Segment Leadership and Growth Trends
Biomarker Testing Services Market Share (%), Service, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the biomarker testing services market, Biomarker Assay Development & Validation held the dominant position in 2025 with a 48.52% share. its position is underpinned by the central role assay development and validation play in making biomarkers usable in clinical and research settings, where reproducibility, sensitivity, and regulatory readiness are essential. This service remains foundational because pharmaceutical companies, diagnostic developers, and research organizations rely on validated assays before biomarker programs can move into broader testing, patient stratification, or commercialization workflows.
Flow Cytometry is emerging as the fastest-growing service in the biomarker testing services market as demand increases for high-resolution cellular analysis in translational research and precision medicine programs. Its momentum is backed by the practical need to evaluate complex immune and cell-based responses more efficiently than conventional methods allow, particularly in studies where multiparametric characterization is critical. Compared with more routine service categories, Flow Cytometry is gaining traction because it aligns closely with evolving biomarker requirements in advanced therapeutic development and immunologically driven research.
Application Segment Analysis: Oncology (Largest Segment) vs Drug Discovery & Development (Fastest-Growing Segment)
Oncology accounted for the largest position in the biomarker testing services market in 2025, representing a 53.95% share. This leadership reflects the established use of biomarkers in cancer detection, patient stratification, treatment selection, and disease monitoring, where testing services are closely tied to routine clinical decision pathways and targeted therapy development. The segment maintains its share because oncology continues to require extensive biomarker support across both clinical practice and sponsored research, creating sustained service demand with clear operational relevance.
Drug Discovery & Development is the fastest-growing application in the biomarker testing services market, driven by the expanding use of biomarkers earlier in the development cycle to improve candidate selection and generate more actionable biological evidence. Growth is being reinforced by the practical value of biomarker testing in reducing uncertainty during preclinical and clinical stages, especially as developers seek better ways to identify responsive populations and measure treatment effects. Relative to more established application areas, this segment is advancing quickly because biomarker integration is becoming more embedded in development workflows rather than being treated as a downstream validation tool.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Service | Biomarker Assay Development & Validation, Flow Cytometry, Others | Biomarker Assay Development & Validation | Flow Cytometry |
| Application | Oncology, Drug Discovery & Development, Others | Oncology | Drug Discovery & Development |
| End Use | Pharmaceutical & Biotechnology Companies, Research Institutes, CROs | Pharmaceutical & Biotechnology Companies | CROs |
| Type | Molecular Biomarkers, Cellular Biomarkers | Molecular Biomarkers | Cellular Biomarkers |
Competitive Landscape and Market Positioning
1. IQVIA Holdings Inc. (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. Charles River Laboratories International Inc. (United States)
4. Laboratory Corporation of America Holdings (United States)
5. ICON plc (Ireland)
6. Eurofins Scientific SE (Luxembourg)
7. SGS S.A. (Switzerland)
8. Syneos Health Inc. (United States)
9. Intertek Group plc (United Kingdom)
10. BioAgilytix Labs LLC (United States)
The biomarker testing services market is expanding due to increasing demand for precision diagnostics and targeted treatment approaches. Companies are investing heavily in advanced molecular testing technologies, companion diagnostics, and biomarker discovery research to improve clinical outcomes. Regulatory focus on personalized medicine and early disease detection is also accelerating innovation and service expansion across the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Thermo Fisher Scientific Inc. | Jun-24 | Thermo Fisher Scientific expanded its clinical research laboratory in Wisconsin, increasing its operational footprint to support emerging therapeutic areas. This facility expansion enhances the company's capacity for specialized biomarker testing and clinical development support, strengthening its position in the high-growth segments of precision medicine and advanced molecular diagnostics. |
| Labcorp | Apr-24 | Labcorp expanded its precision oncology portfolio, introducing advanced testing capabilities designed to accelerate drug development programs for biopharma and clinical research partners. This strategic broadening of services supports the increasing industry demand for biomarker-driven trial design, positioning Labcorp to better serve the complex analytical requirements of pharmaceutical companies focused on targeted oncological therapies. |
| Labcorp | Mar-24 | Labcorp launched a blood-based biomarker test for pTau217 to streamline Alzheimer's disease diagnosis and improve clinical trial patient selection. By integrating this high-specificity test into its diagnostic suite, Labcorp enhances its neurodegenerative disease capabilities and provides researchers with a more scalable tool for monitoring disease progression and assessing treatment efficacy in neurological drug development. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Biomarker Testing Services Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Biomarker Testing Services Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of biomarker testing services?
What is the projected value of the biomarker testing services industry by 2035?
How is personalized medicine accelerating demand for biomarker testing services?
Why are pharmaceutical companies expanding outsourcing of biomarker validation activities?
Why does Oncology lead the biomarker testing services market?
Why is Drug Discovery & Development the fastest-growing application segment in the biomarker testing services market?
Why is North America the leading region for biomarker testing services?
What is fueling biomarker testing services market growth in Asia Pacific?
Which companies dominate the biomarker testing services landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization